Given the diminished CSF1R transcript levels in SPP1hi-TAMs (Fig. 1h and Extended Data Fig. 2g), this could partly explain the clinical ineffectiveness of CSF1R antagonism in human patients with cancer compared with pre-clinical models. Here, CSF1R is linked to cancer.